Clinical Trial Update: Ig NextGen 10% in Patients With Primary Immune Deficiency (PID) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Ig NextGen 10% in patients with primary immunodeficiency diseases has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Diseases

Drugs mentioned

• Ig NextGen 10%

Snippet

Sponsor: CSL Limited | Conditions: Primary Immune Deficiency (PID) | Phase 3 | Status: COMPLETED